Alterations in LRIG1 gene may increase the risk for breast cancer relapse and death

May 30, 2014

(Medical Xpress)—Women whose early-stage breast cancers had reduced numbers of copies of the LRIG1 gene were more likely to have a relapse or die of their disease, according to data published in Cancer Research, a journal of the American Association for Cancer Research.

"Tumors with metastatic capability have cells within them that have stem cell-like properties, which resist chemotherapy, tend to sit quietly in the tumor, and are most likely the source of metastatic spread," said Patricia A. Thompson, Ph.D., an associate professor in the Department of Cellular and Molecular Medicine and leader of the Cancer Prevention and Control Program at the University of Arizona Cancer Center in Tucson. "LRIG1 is a protein that is thought to control the growth of these cells and keep them quiet."

Human cells have two copies of most genes. An increase or decrease in copy-number of certain genes is implicated in several diseases, including cancer.

Among women who were diagnosed with stage 1 or stage 2 breast cancers, those whose tumors had loss of LRIG1 copy-numbers were almost twofold more likely to have a relapse, 2.39-fold more likely to have a relapse five years after diagnosis or later, and 1.55-fold more likely to die of their disease, compared with those whose tumors did not have loss of LRIG1 copy-numbers. Stage 1 and stage 2 breast cancers are generally considered to be at a lower risk for a relapse. These results could help clinicians identify those at increased risk and monitor them more carefully.

"First, we found that the loss of LRIG1 gene copy-numbers in tumors of early-stage patients was associated with a higher risk of disease relapse, metastasis, and death," said Thompson. "Second, we observed that the patients whose tumors had an increase in the copy-numbers of LRIG1 had much better clinical and pathology characteristics, generally. This suggested that the gain of LRIG1 copy-numbers may contribute to the lower risk observed in these patients."

Thompson and colleagues used breast cancer tissue samples from 971 women who were treated at MD Anderson Cancer Center for stage 1 or stage 2 breast cancers between 1985 and 2000. This analysis was a joint collaboration between investigators at MD Anderson Cancer Center and the Baylor College of Medicine in Houston, and the University of Umeå in Sweden.

They used a high-resolution molecular inversion probe array with 300,000 probes, 12 of which detected alterations in LRIG1. This technology is best suited for samples that have been stored for long periods of time and was vital for this project, said Thompson.

Of the 971 samples, 3.7 percent had gain, and 8.9 percent had losses in LRIG1 copy-numbers. The researchers also found that LRIG1 copy-number loss was more common in triple-negative (13.8 percent) and HER2-positive (12.3 percent) breast cancers, which have worse prognosis, compared with luminal A and luminal B subtypes (less than 10 percent).

LRIG1 copy-number loss was also more prevalent in samples from black and Hispanic women (12.8 and 12.2 percent, respectively), who often have worse breast cancer outcomes, compared with samples from non-Hispanic white women (7.7 percent).

The researchers found that LRIG1 copy-number loss was significantly associated with disease relapse, distant metastasis, and death.

The researchers next used data from pooled, publicly available data sets yielding 1,576 samples to analyze alterations in LRIG1 and found that low expression of this gene was associated with increased distant metastasis and death, compared with medium or high expression. "Given that these results are such a strong replication of our findings from really old samples, we were very excited," said Thompson.

Outcomes from these two analyses did not change even after adjusting for known factors that influence relapse and metastasis, leading the researchers to conclude that alteration in LRIG1 copy-numbers is an independent risk factor for and death in otherwise low-risk patients.

"Measurement of the expression levels of LRIG1 as RNA or protein would be more clinically relevant and we would like to see the development of such an assay," said Thompson. "Efforts in developing LRIG1 as a tumor marker would help in developing new agents to kill or silence these cells as a means to prevent relapse and metastasis.

"Our ability to identify patients as being at high risk for versus at those at very low risk is dramatically improving," Thompson added.

Explore further: Tales from the crypt lead researchers to cancer discovery

Related Stories

Tales from the crypt lead researchers to cancer discovery

March 30, 2012
Tales from the crypt are supposed to be scary, but new research from Vanderbilt University, the HudsonAlpha Institute for Biotechnology and colleagues shows that crypts can be places of renewal too: intestinal crypts, that ...

Regulator of gene expression responsible for the progression of breast cancer

February 28, 2014
Yale Cancer Center researchers have identified a regulator of gene expression that is responsible for the progression of breast cancer and its metastasis to the lung. The study appears online in Cell Reports.

Increased risk for breast cancer death among black women greatest during first 3 years postdiagnosis

October 28, 2012
Non-Hispanic black women diagnosed with breast cancer, specifically those with estrogen receptor-positive tumors, are at a significantly increased risk for breast cancer death compared with non-Hispanic white women.

Researchers identify a new suppressor of breast metastasis to the lung

May 27, 2014
A study published today in EMBO Molecular Medicine reveals that the loss of function of the gene RARRES3 in breast cancer cells promotes metastasis to the lung.

Two new possible drug targets for triple negative breast cancer

May 27, 2014
The suppression of two genes reduce breast cancer tumor formation and metastasis by interfering with blood vessel formation and recruitment, report scientists from Houston Methodist and five other institutions in the Proceedings ...

Gene implicated in progression and relapse of deadly breast cancer

March 24, 2014
Scientists from Weill Cornell Medical College and Houston Methodist have found that a gene previously unassociated with breast cancer plays a pivotal role in the growth and progression of the triple negative form of the disease, ...

Recommended for you

Cancer-death button gets jammed by gut bacterium

July 27, 2017
Researchers at Michigan Medicine and in China showed that a type of bacterium is associated with the recurrence of colorectal cancer and poor outcomes. They found that Fusobacterium nucleatum in the gut can stop chemotherapy ...

Researchers release first draft of a genome-wide cancer 'dependency map'

July 27, 2017
In one of the largest efforts to build a comprehensive catalog of genetic vulnerabilities in cancer, researchers from the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute have identified more than 760 genes ...

Long-sought mechanism of metastasis is discovered in pancreatic cancer

July 27, 2017
Cells, just like people, have memories. They retain molecular markers that at the beginning of their existence helped guide their development. Cells that become cancerous may be making use of these early memories to power ...

Blocking the back-door that cancer cells use to escape death by radiotherapy

July 27, 2017
A natural healing mechanism of the body may be reducing the efficiency of radiotherapy in breast cancer patients, according to a new study.

Manmade peptides reduce breast cancer's spread

July 27, 2017
Manmade peptides that directly disrupt the inner workings of a gene known to support cancer's spread significantly reduce metastasis in a mouse model of breast cancer, scientists say.

Glowing tumor technology helps surgeons remove hidden cancer cells

July 27, 2017
Surgeons were able to identify and remove a greater number of cancerous nodules from lung cancer patients when combining intraoperative molecular imaging (IMI) - through the use of a contrast agent that makes tumor cells ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.